Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weichenthal

Showing results (111-120 of 167) with videos related to

Pageof 17
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und NachsorgeBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Pageof 17

Showing results (111-120 of 167) with videos related to

Sort By:
Pageof 17
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und NachsorgeBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Pageof 17